daunorubicin has been researched along with Androgen-Independent Prostatic Cancer in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Limonta, P; Manea, M; Marzagalli, M; Montagnani Marelli, M; Moretti, RM | 1 |
1 other study(ies) available for daunorubicin and Androgen-Independent Prostatic Cancer
| Article | Year |
|---|---|
Oxime bond-linked daunorubicin-GnRH-III bioconjugates exert antitumor activity in castration-resistant prostate cancer cells via the type I GnRH receptor.
Topics: Antineoplastic Agents; Apoptosis; Cell Proliferation; Daunorubicin; Dose-Response Relationship, Drug; Gonadotropin-Releasing Hormone; Humans; Male; Oximes; Prostatic Neoplasms, Castration-Resistant; Pyrrolidonecarboxylic Acid; Receptors, LHRH; Tumor Cells, Cultured | 2015 |